Medicare AdvantagePrior AuthMedium impact
Tryvio™ (aprocitentan) (Revised)
Humana·Cardiology, Internal Medicine, Family Medicine +1 more·Medicare Advantage
Effective date
Jul 24, 2024
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Tryvio (aprocitentan) tablets for treatment-resistant hypertension. Patients must meet specific criteria including diagnosis of resistant hypertension with 3+ antihypertensive drugs and previous treatment/intolerance to mineralocorticoid receptor antagonists.
Action Required
Immediately: Update prior authorization workflow for Tryvio (aprocitentan) prescriptions for Medicare Advantage patients. Verify patients meet both criteria: (1) treatment-resistant hypertension with 3+ concurrent antihypertensive drug classes, and (2) previous treatment/intolerance/contraindication to mineralocorticoid receptor antagonists. Document these requirements in EMR templates and notify prescribing physicians.